Skip to main content

Articles

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use

ASCO 2017 - Acute Myeloid Leukemia

Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2

ASCO 2017 - Acute Myeloid Leukemia

Outcomes with Lower-Intensity Therapy in TP53-Mutated AML

ASCO 2017 - Acute Myeloid Leukemia

Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study

ASCO 2017 - Acute Myeloid Leukemia

Using a Synthetic Control Arm to Establish Early End Points as Indicators of Overall Survival in Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse

ASCO 2017 - Acute Myeloid Leukemia

Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia

Page 89 of 244
Results 881 - 890 of 2436